TTF1 as a potential prognostic marker for pulmonary adenocarcinoma
Research type
Research Study
Full title
The Potential Prognostic Value of Thyroid Transcription Factor 1 (TTF1) Expression in Pulmonary Adenocarcinoma.
IRAS ID
235928
Contact name
Tegan Ducker
Contact email
Sponsor organisation
Royal Bournemouth Hospital
Duration of Study in the UK
0 years, 3 months, 28 days
Research summary
TTF1 is an antibody used by immunohistochemistry technique and it is usually expressed in lung and thyroid tissue. It is used to confirm the diagnosis of lung cancer (adenocarcinoma subtype). It is being used till now as a qualitative value towards the diagnosis i.e., its expression is referred to as either positive or negative. There is no cohort to quantify it is expression either as a percentage (e.g, 30, 60 or 90% of cells) or intensity (e.g, weak, moderate or strong). A few recent studies suggest that TTF1 expression when quantified, can predict the outcome of the molecular testing of lung cancer (such as EGFR & PDL1). These tests enable the treating clinicians to explore more avenue in the patient's management. My study aims at reaching results & conclusions that might support this assumption.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
17/NW/0721
Date of REC Opinion
18 Dec 2017
REC opinion
Favourable Opinion